Recent News
Theranostics Horizons Spring Edition 2010 Newsletter
Commercial Availability of Enhanced CancerTYPE ID® assay and KRAS/BRAF
bioTheranostics Announces Commercial Agreement with Ferrer inCode
Education Opportunities
Medscape CME/CE
Molecular Classification of Cancers of Uncertain and Unknown Primary
bioTheranostics develops and provides innovative oncology tests to drive personalized treatment.
CancerTYPE ID® provides molecular classification of uncertain or unknown cancer types.
Learn More >
Breast Cancer IndexSM predicts breast cancer recurrence risk based on proprietary molecular biomarkers, H/I and MGI.
Learn More >
Healthcare Professionals
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
Patients and Caregivers
View Patient Testimonial
Learn about CancerTYPE ID
Learn More About Metastatic Cancers
© 2010 bioTheranostics. All rights reserved.
+1 (877) 886-6739 client services
+1 (877) 886-6739 client services
